GBGiorgio Boccarella

Giorgio Boccarella

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Giorgio Boccarella has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    HOG pathway modulation is a determinant of echinocandin treatment failure in Candidozyma auris

    by Dimitrios Sofras, Stef Jacobs, Anitra Zile, Austin Mottola, Alvis Zvirgzdins, Alicia Pageau, Giorgio Boccarella, Hugh Gifford, Vladislav Biriukov, Alexandre K. Dube, et al.

    Candidozyma auris is a rapidly emerging fungal pathogen whose drug-resistant profile poses a formidable challenge to antifungal treatment. Echinocandins are the recommended first-line therapy for invasive C. auris infections, but resistance to this drug class is on the rise. Here we show that, beyond resistance, C. auris can readily acquire genetically encoded echinocandin tolerance, a phenotype of slow but sustained growth and increased survival at concentrations above the minimum inhibitory concentration (MIC) that reflects incomplete maximal inhibition and a reduced Hill coefficient without an increase in MIC. Tolerance was therefore undetectable by standard clinical susceptibility testing, yet it significantly reduced treatment efficacy in an immunocompromised murine model of systemic infection. Genetic dissection revealed that tolerance arises through disruption of the high-osmolarity glycerol (HOG) mitogen-activated protein kinase (MAPK) pathway through the loss of function of Ssk1, Ssk2, Pbs2 or Hog1, or specific substitutions in Nik1. The disruption of the HOG pathway did not confer fitness or virulence defects in C. auris, and in Candida albicans and Nakaseomyces glabratus, it did not confer tolerance, suggesting a unique non-essential rewiring of this pathway in C. auris. Proteomic and cell-wall analyses linked tolerance to altered cell-wall remodelling during echinocandin exposure. Evolutionary modelling and deep sequencing of FKS1 hotspots in experimentally evolved populations showed that tolerance increases the rate at which resistance-conferring FKS1 hotspot substitutions emerge. Putative high-impact mutations in HOG pathway effectors in clinical isolates suggest that this phenotype occurs in patients, where it might reduce treatment efficacy or facilitate resistance emergence. This work therefore identifies HOG-mediated acquired tolerance as a hidden clinically relevant direct and indirect determinant of echinocandin treatment failure.

  • Open Access

    Bacterial Persistence Modulates the Speed, Magnitude, and Onset of Antibiotic Resistance Evolution

    by Giorgio Boccarella, Philip Ruelens, Ernesto Berríos-Caro, Bram Van Den Bergh, Lloyd Cool, Jan Michiels, Pieter van Den Berg

    Bacterial persistence, a phenomenon where a subpopulation of cells can exhibit increased survival to antibiotic stress, allows part of the population to withstand antibiotic treatment. This can have far-reaching implications for the evolution of antibiotic resistance, yet its evolutionary consequences remain insufficiently understood. Here, using a combination of evolutionary modeling and experimental evolution data on Escherichia coli, we show that persistence impacts the speed, onset, and magnitude of antibiotic resistance evolution. Specifically, high persistence facilitates the slow establishment of small-effect mutations by protecting them from antibiotic killing, while low persistence boosts the rapid yet unpredictable emergence of rare large-effect resistance mutations by amplifying their competitive advantage. Our results show that persistence level has a critical impact on the trade-off between short-term population survival and the evolution of high-level resistance, with distinct outcomes depending on the severity of the antibiotic treatment regimen. These findings provide key insights for designing antibiotic treatment strategies that minimize the risk of antibiotic resistance evolution while maintaining treatment efficacy.